| Online-Ressource |
Verfasst von: | Passweg, Jakob R. [VerfasserIn]  |
| Giagounidis, Aristoteles [VerfasserIn]  |
| Simcock, Mathew [VerfasserIn]  |
| Aul, Carlo [VerfasserIn]  |
| Dobbelstein, Christiane [VerfasserIn]  |
| Stadler, Michael [VerfasserIn]  |
| Ossenkoppele, Gert [VerfasserIn]  |
| Hofmann, Wolf-Karsten [VerfasserIn]  |
| Schilling, Kristina [VerfasserIn]  |
| Tichelli, André [VerfasserIn]  |
| Ganser, Arnold [VerfasserIn]  |
Titel: | Immunosuppressive therapy for patients with myelodysplastic syndrome |
Titelzusatz: | a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care—SAKK 33/99 |
Verf.angabe: | Jakob R. Passweg, Aristoteles A.N. Giagounidis, Mathew Simcock, Carlo Aul, Christiane Dobbelstein, Michael Stadler, Gert Ossenkoppele, Wolf-Karsten Hofmann, Kristina Schilling, André Tichelli, Arnold Ganser |
Jahr: | 2011 |
Umfang: | 7 S. |
Fussnoten: | Published online ahead of print on December 13, 2010 ; Gesehen am 22.09.2022 |
Titel Quelle: | Enthalten in: Journal of clinical oncology |
Ort Quelle: | Alexandria, Va. : American Society of Clinical Oncology, 1983 |
Jahr Quelle: | 2011 |
Band/Heft Quelle: | 29(2011), 3, Seite 303-309 |
ISSN Quelle: | 1527-7755 |
Abstract: | PURPOSE: Immunosuppressive treatment is reported to improve cytopenia in some patients with myelodysplastic syndrome (MDS). Combined antithymocyte globulin (ATG) and cyclosporine (CSA) is most effective in patients with immune-mediated marrow failure. - PATIENTS AND METHODS: This trial was designed to assess the impact of immunosuppression on hematopoiesis, transfusion requirements, transformation, and survival in patients with MDS randomly assigned to 15 mg/kg of horse ATG for 5 days and oral CSA for 180 days (ATG+CSA) or best supportive care (BSC), stratified by treatment center and International Prognostic Scoring System (IPSS) risk score. Primary end point was best hematologic response at 6 months. Eligible patients had an Eastern Cooperative Oncology Group performance status of ≤ 2 and transfusion dependency of less than 2 years in duration. - RESULTS: Between 2000 and 2006, 45 patients received ATG+CSA (median age, 62 years; range, 23 to 75 years; 56% men) and 43 patients received BSC (median age, 65 years; range, 24 to 76 years; 81% men). IPSS score was low, intermediate-1, intermediate-2, high, and not evaluable in eight, 24, seven, one, and five patients on ATG+CSA, respectively, and eight, 25, five, zero, and five patients on BSC, respectively. Refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess of blasts (RAEB) -I, RAEB-II, and hypoplastic disease were present in 21, six, nine, zero, and nine patients on ATG+CSA, respectively, and 18, eight, 11, two, and four patients on BSC, respectively. By month 6, 13 of 45 patients on ATG+CSA had a hematologic response compared with four of 43 patients on BSC (P = .0156). Two-year transformation-free survival (TFS) rates were 46% (95% CI, 28% to 62%) and 55% (95% CI, 34% to 70%) for ATG+CSA and BSC patients, respectively (P = .730), whereas overall survival (OS) estimates were 49% (95% CI, 31% to 66%) and 63% (95% CI, 42% to 78%), respectively (P = .828). - CONCLUSION: This open-label randomized phase III trial demonstrates that ATG+CSA treatment seems to be associated with hematologic response in a subset of patients without apparent impact on TFS and OS. |
DOI: | doi:10.1200/JCO.2010.31.2686 |
URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.1200/JCO.2010.31.2686 |
| DOI: https://doi.org/10.1200/JCO.2010.31.2686 |
Datenträger: | Online-Ressource |
Sprache: | eng |
Sach-SW: | Adult |
| Aged |
| Antilymphocyte Serum |
| Cell Transformation, Neoplastic |
| Cross-Over Studies |
| Cyclosporine |
| Drug Therapy, Combination |
| Female |
| Health Services |
| Humans |
| Immunosuppressive Agents |
| Intention to Treat Analysis |
| Logistic Models |
| Male |
| Middle Aged |
| Myelodysplastic Syndromes |
| Prospective Studies |
| Survival Analysis |
K10plus-PPN: | 1817289659 |
Verknüpfungen: | → Zeitschrift |
Immunosuppressive therapy for patients with myelodysplastic syndrome / Passweg, Jakob R. [VerfasserIn]; 2011 (Online-Ressource)